What does it do?
ExlService is a growth-stage business that earns money by providing data analytics and AI-led digital operations to large corporations. The company acts as an essential operating partner for industries like insurance and healthcare, handling everything from claims processing to clinical data management. Money flows through long-term service contracts where clients pay based on the volume of transactions processed or the number of specialized employees assigned to their account. EXL is currently shifting its pricing model to "outcome-based" fees, where it keeps a portion of the costs its AI software saves for the client. This transition is moving the company from a traditional outsourcing firm to a high-value technology partner.
Where does revenue come from?
The majority of revenue comes from the Insurance and Analytics segments, which together represent roughly 60% of total sales. The Insurance segment provides end-to-end policy administration and claims handling, while the Healthcare and Life Sciences unit, which grew revenue 22% last quarter, manages member engagement and payment integrity. The Analytics segment focuses on building predictive models and AI platforms that help banks and retailers understand customer behavior.
Revenue Breakdown
Revenue by Geography
Who are its customers?
ExlService serves the world's leading corporations in highly regulated industries, including over 17 new enterprise clients won in the second quarter of 2026 alone. The company is deeply embedded in the insurance sector, where its LifePRO platform serves dozens of major insurers, and in healthcare, where it manages care for millions of patients through its clinical platforms. While the total number of enterprise clients is not disclosed as a single headline figure, the company serves hundreds of large-scale organizations, including many of the Fortune 500. Retention is exceptionally high because the company’s employees and software are integrated into the client's daily regulatory and financial workflows.
What gives it staying power?
Staying power comes from high switching costs and a proprietary data moat built over 25 years. Once EXL integrates its AI agents and data platforms into a client's claims or clinical systems, removing them would cause massive operational disruption and regulatory risk.
Where is it headed?
ExlService is betting its future on "agentic AI," where autonomous digital workers replace human labor in complex business tasks. Management is investing heavily in the EXLerate.ai platform to move the business away from hiring thousands of people toward selling high-margin software solutions. If successful, this shift could significantly expand profit margins as the cost to serve each client drops while the value delivered rises.
Revenue is growing at a mid-teens rate as the company successfully layers new AI services onto its established client base. Second quarter 2026 revenue rose 15.6% to $594.8 million, showing that demand for data modernization is accelerating rather than cooling.
Free cash flow tracks net income closely, allowing the company to fund large acquisitions like the $310 million iMerit deal entirely from its own operations. The business generated $300 million in free cash flow in 2025, which represents a healthy 14.3% margin on total sales.
The balance sheet is strong with a conservative debt-to-equity ratio of 0.56, though current liabilities spiked to $703.6 million in June 2026 to fund the iMerit acquisition. While cash balances dipped to $126.7 million, the company recently secured a new $1 billion credit facility to maintain its aggressive pursuit of AI technology.
ExlService is a financially disciplined growth business that is using its strong cash flow to pivot toward higher-margin software and AI services.
ExlService does not pay a dividend, choosing instead to use nearly all its excess cash to buy back its own shares and fund technology acquisitions. It has spent over $1.1 billion on treasury shares, and the share count has fallen by roughly 7% over the last two years, meaning each remaining share now owns a bigger slice of the business. This aggressive buyback program effectively returns cash to owners by boosting the value of their holdings rather than sending out a quarterly check. We view this as a growth-oriented capital policy that works well as long as the company can keep earning a high 17.7% return on the capital it reinvests.
The Healthcare and Life Sciences segment is seeing explosive demand, with revenue growing 22% year-over-year in the most recent quarter. This growth is driven by hospital systems and insurers using EXL's data platforms to automate clinical documentation and payment integrity checks. The high gross margin of 46.9% in this segment proves that these specialized services are far more profitable than generic business processing.
Operating margins are under slight pressure as the company front-loads investment into its AI platforms and integration costs. GAAP operating margin fell to 14.7% this quarter from 15.8% a year ago, reflecting the costs of the iMerit acquisition and higher stock-based compensation for AI talent. Investors should watch whether the "adjusted" operating margin, which held steady at 19.7%, eventually translates into higher GAAP profits as the AI pivot scales.
The global data analytics and AI services market is approximately $525 billion today and is growing at 7% annually, putting it on track to exceed $700 billion by 2031. It is a highly attractive industry because clients are moving away from simple cost-cutting toward "outcome-linked" contracts that reward vendors for measurable business improvements. The single biggest force shaping the industry is the shift from manual labor to agentic AI, which is turning service providers into technology platforms. ExlService stands as a specialized leader in this market, holding a dominant position in the insurance and healthcare niches where data complexity is highest.
The competitive dynamic is rationally structured but intense, as barriers to entry have risen from simple low-cost labor to sophisticated AI and data capabilities. The industry is consolidating around players who can prove their AI models work at enterprise scale, which protects the pricing power of established leaders.
The primary threat comes from Genpact, which has a larger global footprint and can bundle similar services at a competitive price. EPAM and Accenture attack from the high-end consulting side, threatening to take away the strategic AI development work. The most dangerous threat is the "insourcing" risk, where clients might use generic generative AI tools to automate their own operations instead of hiring EXL.
ExlService is holding its ground and gaining share in high-margin segments like healthcare, as evidenced by its 22% growth in that unit. The company's win of 17 new enterprise clients last quarter proves its specialized AI message is resonating better than the generic offerings of larger rivals.
The primary source of protection is high switching costs built into the core business processes of its clients. EXL does not just provide software; it runs the actual claims and clinical operations for insurers, making it an inseparable part of their regulatory and financial structure. Removing EXL would require a client to re-engineer their entire back office, creating a level of risk few CEOs are willing to take.
The financial metrics prove this advantage is real, as a TTM ROIC of 17.7% sits comfortably above the company's cost of capital. The combination of mid-teens revenue growth and expanding healthcare margins proves that EXL possesses real pricing power in its most specialized segments. The results are consistent with a durable moat that is currently benefiting from a massive technology tailwind.
The moat is strengthening as the company integrates iMerit’s AI training technology into its existing platforms. This moves the company further away from commoditized labor and toward a unique data position that rivals cannot easily replicate.
Raised FY2026 revenue guidance from 12% to 16% growth after Q2.
$310M iMerit acquisition funded via FCF and $1B credit facility.
CEO Rohit Kapoor is a co-founder with over 25 years of tenure.
Capital Allocation Track Record
Rohit Kapoor is a co-founder CEO with a quarter-century of tenure, and his leadership has been defined by a disciplined evolution from labor outsourcing to a data-and-AI-first strategy. Management has built high credibility by consistently beating earnings estimates for four consecutive quarters and successfully raising full-year guidance as the AI pivot gains traction. Their judgment in acquiring iMerit for $310 million shows a willingness to make bold, calculated bets to secure technical leadership in the generative AI race.
The primary governance risk is key-person dependency on Kapoor, whose vision has been the central driver of the company's high-return strategy since 1999. While the recent appointment of Bhupender Singh as President of International Growth Markets signals a broadening of the leadership bench, the thesis remains heavily tied to Kapoor's ability to navigate the AI transition. Insider ownership is substantial, and the board’s decision to pursue aggressive share buybacks instead of a dividend aligns management’s interests with long-term shareholders focused on per-share value growth.
We expect revenue to grow from $2.4B in FY2026 to $3.9B in FY2031 (~10% CAGR), with EPS growing from $2.29 to $4.24 (~13% CAGR). Growth is driven by insurance and healthcare companies shifting from basic outsourcing to advanced data analytics and AI-driven operations. Profit margins rise slightly as the business shifts toward high-value data analytics software which costs less to deliver than manual labor. EPS grows faster than revenue because the company is buying back shares and margins are expanding at the same time. Operating margin expected to reach ~16% by FY2031.
AI platform adoption drives a shift to outcome-based pricing models. If EXLerate.ai becomes the standard for insurance automation, EXL can charge based on the value it creates rather than hours worked, significantly expanding margins.
Healthcare segment continues growing at double-digit rates. Deepening penetration into healthcare clinical data and payment integrity offers a massive, high-margin runway as US providers modernize their data stacks.
M&A strategy adds specialized AI foundation model expertise. Successful integration of iMerit and future acquisitions could give EXL a technical edge that rivals like Genpact or WNS cannot easily replicate.
Generative AI tools allow clients to automate operations in-house. If frontier models from OpenAI or Anthropic become easy for insurers to use themselves, the demand for EXL's specialized AI services could evaporate.
Labor cost inflation in India and Philippines outpaces AI automation. If the transition to AI software takes longer than expected, rising wages for its 68,000 employees could squeeze margins in the core service business.
Large-scale data breach at a major insurance or healthcare client. As EXL manages more sensitive healthcare data, a single security failure could cause massive reputational damage and permanent client loss.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We value ExlService based on its long-term profit potential as it transforms into an AI-led business. The company is moving away from low-cost labor and toward high-margin software agents. Using a simple multiple on today's earnings would miss the massive shift happening in how the company actually makes money.
A profit estimate of $4.24 in five years multiplied by a 25x multiple gives a future price of $106, which is worth $71 today. We arrived at this by discounting that future price back to today's dollars at a 10% annual rate. This 25x multiple is at the bottom of the 24x to 40x range the stock has traded in over the last five years and sits level with rivals like EPAM (25x) while staying well below faster-growing data firms like Verisk (35x).
Priced instead on its average 30x multiple against next year's earnings, we get $78—very close to our $71 valuation. While rivals like Genpact and WNS trade at much lower multiples near 15x, they are not growing their AI and data segments as quickly as ExlService. If we were to use that lower 15x multiple, the stock would only be worth $39, but that would ignore the 15% annual growth and high-margin transition currently underway.
The biggest risk is that "agentic AI" tools allow clients to automate their own business processes, cutting out ExlService entirely. This would cause revenue to shrink by 15% to 20% as old contracts are not renewed, pushing the fair value down toward $39. Watch for any rise in client churn or a drop in new contract wins in the quarterly reports.
Bear case ($45): AI automation tools become so easy to use that clients handle workflows themselves, bypassing service providers entirely; or Net margins fail to expand and instead drop toward 8% as competition for AI talent drives up employee costs.
Bull case ($85): The iMerit acquisition accelerates revenue growth beyond 20% as EXL wins massive contracts with AI model builders; or Software-like profit margins arrive early, pushing net margins above 16% as automated agents handle the bulk of processing tasks.
Clearthesis wrote this report from 45 sources, including SEC filings, analyst estimates, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on September 2, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.